Kampo, Japan ’s Traditional Medicine
Tracing the origin of Kampo, Japan ’s traditional medicine which surprisingly, could be in 8th century, suggests researchers in Japan and China (Source: Disabled World)
Source: Disabled World - November 11, 2022 Category: Disability Tags: Alternative Medicine Source Type: news
Woman, 62, told tea intake was cause of her liver injury - made her eyes turn yellow
The concerning incident suggests caution should be exercised when using herbal remedies. (Source: Daily Express - Health)
Source: Daily Express - Health - November 11, 2022 Category: Consumer Health News Source Type: news
Fertility clinics warn against TikTok pregnancy advice as people turn to herbal teas and horoscopes
Doctors and scientists are urging people not to take TikTok fertility advice as fact as people sell teas, horoscope readings and fertility boosting recipes to people who are struggling to get pregnant. (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2022 Category: Consumer Health News Source Type: news
Mindfulness Program Equals Antidepressants in Easing Anxiety Disorders
(Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 10, 2022 Category: Psychiatry Tags: Psychiatry, Alternative Medicine, News, Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
